Warnings, Columns-Drugs & Supplements, April 2006

April 1, 2006

Adverse Events Reported in 6 of 8 TGN1412 Clinical Trial Volunteers LONDON, England - England's Medicines and Healthcare products Regulatory Agency is reporting serious adverse events associated with TeGenero AG's and Boehringer Ingelheim's leukemia, autoimmune and inflammatory diseases TGN1412 drug. The MHRA said on April 5 that six of the eight male volunteers who had enrolled in a recently suspended clinical trial "experienced a life-threatening incident of 'Cytokine Release Syndrome.'" "This occurs when the substance release by activated T cells produces a type of systemic inflammatory response," the MHRA said. According to the MHRA, Parexel, … Subscribe Now Purchase Article for $40.00 Registered User Log In Email Address Password Login Forgot your username or password? UPCOMING CONFERENCES HarrisMartin's MDL Conference: Video Game Addiction and the Latest Mass Tort Updates May 29, 2024 - Salt Lake City, UT The Grand America Hotel MORE DETAILS HarrisMartin's Mass Tort Settlements Conference - Sponsored by Milestone June 27, 2024 - Buffalo, NY The Richardson Hotel Buffalo MORE DETAILS Sign Up For Email Alerts × Email address Publications Asbestos Benzene & Emerging Toxic Torts Litigation Camp Lejeune & Water Contamination Drugs & Medical Devices MDL Mass Tort & Class Action Monitor Reinsurance & Arbitration Talcum Powder Litigation Report Close Submit